VL-2397
Also known as: Acremonium persicinum antifungal peptide, ASP2397, VL-2397
Source VL-2397 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
VL-2397 (also called ASP2397) is a synthetic cyclic peptide under clinical investigation for the treatment of invasive aspergillosis and other serious fungal infections.
Mechanism of Action
Enters fungal cells via the Sit1 transporter and disrupts iron homeostasis, causing rapid fungal cell death
Routes of Administration
Goals & Uses
- Treatment of invasive aspergillosisAntifungalModerate
- Treatment of azole-resistant Aspergillus infectionsAntifungal TherapyModerate
- Other invasive mold infectionsAntifungal TherapyLow
- Invasive aspergillosisAntifungalModerate
- Salvage therapy for refractory invasive aspergillosisAntifungal TherapyLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Known hypersensitivity to VL-2397AllergyHigh
- Known hypersensitivity to VL-2397 or any component of the formulationAllergyHigh
Adverse Effects
- HypokalemiaElectrolyteUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Elevated liver enzymes (transaminases)HepaticUncommon
- Elevated liver enzymesHepaticUnknownIncrease in AST/ALT or other hepatic markers
- Infusion-related reactionsHypersensitivityCommon
Drug Interactions
- Strong CYP3A4 inhibitors/inducersLow
- Other nephrotoxic agentsModerate
- CYP450 substratesLow
Population Constraints
- Pediatric patientsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
- Pediatric patients <12 yearsAgeRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization granted.
- United StatesInvestigationalIND in place; Phase 2/3 trials ongoing.
- United KingdomInvestigationalUnder MHRA clinical trial oversight.
Currently in Phase 2/3 clinical trials; not approved in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is VL-2397?
VL-2397 (also called ASP2397) is a synthetic cyclic peptide under clinical investigation for the treatment of invasive aspergillosis and other serious fungal infections.
What is VL-2397 used for?
VL-2397 is educationally associated with: Treatment of invasive aspergillosis, Treatment of azole-resistant Aspergillus infections, Other invasive mold infections, Invasive aspergillosis, Salvage therapy for refractory invasive aspergillosis. Educational only — not medical advice.
How is VL-2397 administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of VL-2397?
Reported adverse effects include: Hypokalemia, Headache, Nausea, Elevated liver enzymes (transaminases), Elevated liver enzymes, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid VL-2397?
Recorded contraindications: Severe hepatic impairment, Known hypersensitivity to VL-2397, Known hypersensitivity to VL-2397 or any component of the formulation. Consult a qualified clinician before use.